Methods for diagnosing a homologous recombination deficiency in human tumors

HK40137372APending Publication Date: 2026-09-11INSTITUT CURIE +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124777
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-28
Filing Date
2026-06-12
Publication Date
2026-09-11

Smart Images

  • Figure 00000022_0000
    Figure 00000022_0000
  • Figure 00000023_0000
    Figure 00000023_0000
  • Figure 00000024_0000
    Figure 00000024_0000
Patent Text Reader

Abstract

The present invention pertains to an improved method for the diagnosis of homologous recombination deficiency (HRD) in a tumor The method according to the invention particularly comprises evaluating the number of large-scale genomic alterations (LGA) by obtaining the copy number alterations (CNA) profile by shallow coverage whole genome sequencing (sWGS) in a tumor sample, and determining a LGA-score which corresponds to the LGA number adjusted by the genome complexity of the tumor and the presence of one or two markers selected from the group of markers consisting of (1) cyclin dependent kinase 12 (CDK12) mutation-associated phenotype with multiple interstitial gains in the CNA profile, (2) Cyclin E1 (CCNE1) amplification, (3) human epidermal growth factor receptor-2 (HER2) amplification and (4) multifocal amplification phenotype.
Need to check novelty before this filing date? Find Prior Art

Description

Abstract This invention relates to an improved method for diagnosing homologous recombination defects (HRD) in tumors. The method according to the invention specifically includes assessing the number of large-scale genomic variations (LGAs) by obtaining a copy number variation (CNA) profile in a tumor sample via low-coverage whole-genome sequencing (sWGS) and determining an LGA score corresponding to the number of LGAs adjusted for tumor genomic complexity and the presence of one or two biomarkers selected from the group consisting of: (1) cyclin-dependent kinase 12 (CDK12) mutation-associated phenotypes with multiple mesenchymal gains in the CNA profile, (2) cyclin E1 (CCNE1) amplification, (3) human epidermal growth factor receptor-2 (HER2) amplification, and (4) multifocal amplification phenotypes.

Claims

Claims

1. A method for diagnosing a homologous recombination deficiency (HRD) in a tumor, said method comprising the steps of:- evaluating the number of large-scale genomic alterations (LGA) by obtaining the copy number alterations (CNA) profile by shallow coverage whole genome sequencing (sWGS) in a tumor sample,- determining a LGA-score which corresponds to the LGA number adjusted by the genome complexity of the tumor and the presence of a marker selected from the group of markers consisting of (1) cyclin dependent kinase 12 (CDK12) mutation-associated phenotype with multiple interstitial gains in the CNA profile, (2) Cyclin E1 (CCNE1) amplification, (3) human epidermal growth factor receptor-2 (HER2) amplification and (4) multifocal amplification phenotype.

2. The method according to claim 1 , wherein said sample is selected from fresh tumors samples and preserved tumor samples such as frozen tumor samples and formalin-fixed paraffin embedded (FFPE) tumor samples.

3. The method according to claim 2, wherein said tumor sample is a formalin-fixed paraffin embedded (FFPE) sample of the tumor and wherein the sWGS CNA profile has been corrected by eliminating the FFPE noise profile.

4. The method according to any one of claims 1 to 3, wherein a high LGA-score is associated with HRD and a low LGA-score is associated with HR pathway proficiency (HRP), and wherein borderline case are resolved by taking into account:- the genome complexity of the tumor;- LGA_max, the upper bound of LGA number found in segmented copy number profile;- the presence of a marker selected from the group of markers consisting of (1) cyclin dependent kinase 12 (CDK12) mutation-associated phenotype with multiple interstitial gains in the CNA profile, (2) Cyclin E1 (CCNE1) amplification, (3) human epidermal growth factor receptor-2 (HER2) amplification and (4) multifocal amplification phenotype^

5. The method according to any one of claims 1 to 4 wherein said tumor is a breast tumor.

6. The method according to any one of claims 1 to 4, wherein said tumor is an ovarian tumor.

7. A method for predicting the efficacy of a treatment in a patient suffering from cancer, wherein said treatment comprises a PARPi and / or an alkylating agent, and wherein said method comprises diagnosing HRD in a tumor sample according to the method of any one of claims 1 to 6.

8. A PARPi and / or an alkylating agent for use in a method for treating a cancer in a patient, wherein said patient has been diagnosed as having a tumor presenting a HRD according to the method of any one of claims 1 to 6.